Abstract:In 2011, NBTXR3 emerged as the first-in-class radioenhancer used in clinical practice for treating patients with locally advanced soft tissue sarcoma (LA-STS). NBTXR3 became the first radioenhancer to receive CE mark approval after successfully completing a phase II/III clinical study for LA-STS with a doubling of the pCR rate in the NBTXR3 arm compared with the control arm. NBTXR3 nanoparticles consist of a functionalized core of hafnium oxide, a high atomic number element, specifically designed to amplify the effects of radiotherapy (RT) within cells without additional side effects on healthy tissues. Leveraging this physical mechanism, RT-activated NBTXR3 (NBTXR3+RT) has demonstrated superior efficacy in destroying tumor cells and controlling tumor growth in numerous preclinical models and in human, surpassing the effects of RT alone, while maintaining a favorable safety profile. Preclinical studies have revealed that the benefits of NBTXR3 extend beyond mere radioenhancement and improved cancer cell destruction. Specifically, NBTXR3 has been reported to possess immunomodulatory properties through 1) improved induction of DNA damage, leading to better activation of the cGAS-STING pathway, 2) promotion of immunogenic cell death, 3) enhancement of immunopeptidome presentation, 4) generation of an antitumor immune response leading to the production of an abscopal effect mediated by CD8+ cytotoxic lymphocytes. Notably, a series of recent studies using a two-tumor mouse model of anti-PD1-resistant lung cancer that the addition of NBTXR3 significantly improved the efficacy of various treatment regimens (RT+anti-PD1 and combinations with other check-point inhibitors) in terms of tumor growth, abscopal effect, and survival. It has been demonstrated that same benefits can be achieved when NBTXR3 was combined with proton therapy. Moreover, all these studies (X-ray and proton) reported a robust activation of the antitumor immune response, restoration of the effectiveness of anti-PD1 therapy, and the induction of memory response in cured mice. However, our understanding of the biological events leading to these effects remains limited. To address this question, we conducted a series of in vitro studies that employed cytometry, microscopy, and RNA sequencing on various cancer models, both human and murine. We reported that NBTXR3 nanoparticles primarily accumulate within lysosomes following their uptake by tumor cells, leading to the activation of genes associated with the biogenesis, structure, and contents of these organelles. Upon activation by RT, NBTXR3 within lysosomes induces lysosomal membrane permeabilization (LMP), resulting in an increase in lipid peroxidation, inducing regulation of fatty acid oxidation genes, and impacting mitochondrial genes expression, such as respirasome. These findings provide a deeper insight into the early biological effects of NBTXR3+RT in comparison to RT alone. Citation Format: Jordan Da Silva, Celia Bienassis, Sebastien Paris. Analysis of cancer cells response to radiotherapy activated NBTXR3 nanoparticles [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2870.

BIBR1532 combined with radiotherapy induces ferroptosis in NSCLC cells and activates cGAS-STING pathway to promote anti-tumor immunity

Combining radiotherapy with EGFR inhibitor for NSCLC:principle and present status

Combination of irinotecan silicasome nanoparticles with radiation therapy sensitizes immunotherapy by modulating the activation of the cGAS/STING pathway for colorectal cancer

Irradiation Combined with PD-L1−/− and Autophagy Inhibition Enhances the Antitumor Effect of Lung Cancer Via Cgas-Sting-mediated T Cell Activation

Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.

Radiotherapy-activated NBTXR3 nanoparticles promote ferroptosis through induction of lysosomal membrane permeabilization

Biomimetic liposome amplifying mitochondrial damage to potential cancer radio-immunotherapy

Targeting senescence-like fibroblasts radiosensitizes non–small cell lung cancer and reduces radiation-induced pulmonary fibrosis

Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy

Abstract 2870: Analysis of cancer cells response to radiotherapy activated NBTXR3 nanoparticles

Abstract 695: Enhancing radiotherapy with lenvatinib by targeting the CXCL13/CXCR5/NF-ΚB axis

STING Agonist‐Loaded Nanoparticles Promotes Positive Regulation of Type I Interferon‐Dependent Radioimmunotherapy in Rectal Cancer

TGM2-Mediated Autophagy Contributes to the Radio-Resistance of Non-Small Cell Lung Cancer Stem-like Cells

Oxygen self-supplying nanoradiosensitizer activates cGAS-STING pathway to enhance radioimmunotherapy of triple negative breast cancer

I-125 seeds brachytherapy combined with immunotherapy for MET amplification in non-small cell lung cancer from clinical application to related lncRNA mechanism explore: a case report

Abstract SY39-03: Radiation-mediated DNA Sensing Pathway for Immunity and Tumor Regression

Abstract 5762: Engineering cell membrane nanoparticlesenhance immunotherapy and radiodynamic therapy for lung adenocarcinoma by promoting cGAS-STING and ferroptosis

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges

Overexpression of ESYT3 improves radioimmune responses through activating cGAS-STING pathway in lung adenocarcinoma

Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation

Targeting the STAT5A/IDO1 axis overcomes radioresistance and reverses the immunosuppressive tumor microenvironment in NSCLC.